Botulinum Toxin-A for Sialorrhoea Treatment in Asian Adults With Neurological Diseases
Status:
Completed
Trial end date:
2014-04-01
Target enrollment:
Participant gender:
Summary
The efficacy of Botulinum toxin A (BoNT-A) in Asian population has not been properly studied
and there is no literature available on the most efficacious dose of BoNT-A for sialorrhoea
treatment. This research is aimed to find the dose of Dysport® that would be efficacious
without treatment-related adverse events and the duration of effectiveness of the drug for
sialorrhea treatment in Malaysian patients. The efficacy, safety, tolerability and adverse
effects of three doses of Dysport®(50MU, 100MU and 200MU) are examined at 2,6,12 and 24 weeks
post injection in this double-blinding, randomized trial.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
University of Malaya
Treatments:
abobotulinumtoxinA Botulinum Toxins Botulinum Toxins, Type A incobotulinumtoxinA onabotulinumtoxinA